Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes

References

• Swerdlow SH, Campo E, Harris NL, et al. In: Anonymous. WHO classification of tumors of hematopoietic and lymphoid tissues. 4th ed. Loyn: International Agency for Research on Cancer (IARC); 2008.
   Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
   PubMed Web of Science ®Google Scholar
• Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121:3005–3015.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31:2428–2436.
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Padron E, LaBorde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27: 1504–1510.
   PubMed Web of Science ®Google Scholar
• Kroger N, Zabelina T, Guardiola P, et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukemia. A report on behalf of the chronic leukemia working party of the European group for blood and marrow transplantation (EBMT). Br J Haematol. 2002;118:67–73.
   PubMed Web of Science ®Google Scholar
• Symeonidis A, Van Biezen A, Mufti G, et al. Allogeneic stem cell transplantation in patients with chronic myelomonocytic leukemia: the impact of WHO classification and of the conditioning regimen on the transplantation outcome. Annual Meeting of the EBMT 2010, Bone Marrow Transplantation; 2010. p. 45.
   Google Scholar
• Duong H, Akhtari M, Ahn K, et al. Allogeneic hematopoietic cell transplantation for adult chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2015;21:S30–S31.
   PubMedGoogle Scholar
• Symeonidis A, van Biezen A, de Wreede L, et al. Achievement of complete remission predicts outcome of allogeneic hematopoietic stem cell transplantation in patients with chronic myelomonocytic leukemia. A study of the chronic malignancies working party of the European group for blood and marrow transplantation. Br J Haematol. 2015. [Epub ahead of print]. doi: 10.1111/bjh.13576.
   Web of Science ®Google Scholar
• DiNardo CD, Daver N, Jain N, et al. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia. 2014;28:958–961.
   PubMed Web of Science ®Google Scholar
• Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with glucksberg grade. Br J Haematol. 1997;97:855–864.
   PubMed Web of Science ®Google Scholar
• Filipovich AH, Weisdorf D, Pavletic S, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–956.
   PubMed Web of Science ®Google Scholar
• Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778–783.
   PubMed Web of Science ®Google Scholar
• McDonald GB, Sharma P, Matthews DE, et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4:116–122.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Storer B, Storb RF. Validation of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences. Biol Blood Marrow Transplant. 2009;15:757–758.
   PubMed Web of Science ®Google Scholar
• Such E, Cervera J, Costa D, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011;96:375–383.
   PubMed Web of Science ®Google Scholar
• Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99:840–849.
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Itzykson R, Lasho TL, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014;28:2206–2212.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48:452–458.
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Wassie EA, Lasho TL, et al. Blast transformation in chronic myelomonocytic leukemia: risk factors, genetic features, survival, and treatment outcome. Am J Hematol. 2015;90:411–416.
   PubMed Web of Science ®Google Scholar
• Park S, Labopin M, Yakoub-Agha I, et al. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the societe francaise de greffe de moelle et de therapie cellulaire. Eur J Haematol. 2013;90:355–364.
   PubMed Web of Science ®Google Scholar
• Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood. 2006;108:836–846.
   PubMed Web of Science ®Google Scholar
• Alyea EP, Kim HT, Ho V, et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2006;12:1047–1055.
   PubMed Web of Science ®Google Scholar
• Scott BL, Pasquini MC, Logan B, et al. Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): blood and marrow transplant clinical trials network (BMT CTN) 0901. Blood. 2015;126:LBA-8.
   Web of Science ®Google Scholar
• Eissa H, Gooley TA, Sorror ML, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant. 2011;17:908–915.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy P, Lim ZY, Nagi W, et al. Allogeneic hematopoietic SCT for chronic myelomonocytic leukemia: a single-center experience. Bone Marrow Transplant. 2010;45:1502–1507.
   PubMed Web of Science ®Google Scholar
• Orazi A, Germing U. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia. 2008;22:1308–1319.
   PubMed Web of Science ®Google Scholar
• Kerbauy DM, Chyou F, Gooley T, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2005;11:713–720.
   PubMed Web of Science ®Google Scholar